Our products are available in 65 countriesClick here to learn more
Our activities incorporate all areas of the pharmaceutical value chainClick here to learn more
Innovation is one of the pillars of our strategy. We devote approximately EUR 50 million to research and development.Click here to learn more
On the occasion of the national holiday, Dr. István Hodász, CEO of Egis was granted the award ‘For the Hungarian Economy’ by Deputy Prime Minister and Minister of Finance Mihály Varga. The award is the most prestigious recognition to be given by the Minister of Finance on ministerial level for outstanding excellence and contribution to the Hungarian economy.
Egis tied as the most popular employer for science students and young graduates and early-stage professionals, found a new study analysing the preferences of young employees and graduates in Hungary.
As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.
Our Polish branch, Egis Polska, has been present on the market for 25 years and has made a tangible change in the country’s medical reality. Egis Polska introduces innovative medicines, including biological therapies, acts as a respected partner for the medical community, and is recognized as a valued employer, regularly awarded for creating a quality work environment.
PharmaBoardroom is a site for senior professionals, providing global news, trends and reports relating to the pharmaceutical industry.
The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.
Egis ’products are available in 65 countries. Our portfolio consists of 629 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.Learn more about our products